We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eli Lilly has inked a $375 million deal with China-based Eddingpharm for the rights to two legacy antibiotic medicines and manufacturing facility in Suzhou, China.